Appili has assembled a leadership team with expertise in all facets of drug development, from bench to bedside.
Appili’s management team is comprised of experts in drug development, infectious disease and business development. Our collective experience spans large pharma to emerging biopharmaceutical firms, enabling us to rapidly identify promising anti-infective technologies, accelerate their development, and unlock value.
Armand Balboni, MD, PhD
Chief Executive Officer
Armand Balboni's career includes medical research and drug development experience in civilian, academic and military organizations, most recently as a partner at Bloom Burton & Co. where he was the firms senior advisor for regulatory and medical affairs. As an active duty military officer, Dr. Balboni served as a staff officer at the U.S. Army Research Institute of Infectious Diseases (USAMRIID). He completed a military staff fellowship at the U.S. Food and Drug Administration and went on to serve as the deputy director of clinical and regulatory affairs for the U.S. Army. Armand completed his doctoral work in the MD/PhD program at the Icahn School of Medicine at Mount Sinai and earned his law degree at Brooklyn Law School.
Yoav Golan, MD
Chief Medical Officer
Dr. Yoav Golan has an impressive 25+ year career as a medical specialist in infectious diseases. He has served as an attending physician in the Division of Geographic Medicine and Infectious Diseases at Tufts Medical Center, and as an associate professor at Tufts University School of Medicine. His extensive research in the ID space has been published in several books and over 50 peer-reviewed studies in journals, including The New England Journal of Medicine and The Lancet Infectious Diseases. His research focuses on hospital-acquired infections with emphasis on ICU infections, the impact of antibiotic resistance on outcomes, and development of early culture-independent treatment strategies. Dr. Golan’s recent work has focused on C. difficile infections as well as invasive candidiasis. He has been involved in the development of multiple anti-infectives, including, fidaxomicin, ceftaroline and bezlotuximab. He is a member of numerous medical societies, including the Infectious Disease Society of America and the American Society for Microbiology. Dr. Golan is a graduate of the Hadassah School of Medicine at the Hebrew University in Jerusalem, Israel.
Acting Chief Financial Officer
Mr. Howling has over 25 years of healthcare industry experience in senior financial positions; including 11 years with Bausch Health (formerly Biovail Corporation), as Chief Financial Officer, and Senior Vice President, Finance and Corporate Affairs; five years as Chief Financial Officer of Acerus Pharmaceuticals Corporation; and five years as Chief Financial Officer with Pharma Patch PLC. During his career, Mr. Howling has contributed to the success of multiple start-up companies, taken companies through the IPO process, and has collectively raised over US$2.5 billion in various forms of capital. Earlier in his career, Mr. Howling worked in senior financial management positions at Roberts Company Canada Limited, including roles of General Manager, Corporate Secretary and Controller, at GlaxoSmithKline (formerly Beecham Pharmaceuticals Ltd), and as an auditor with PricewaterhouseCoopers. Mr. Howling is a graduate of the ICD/Rotman Director Program and formerly a Certified Public Accountant (inactive license).
Don Cilla, PharmD, MBA
Chief Development Officer
Dr. Cilla brings to Appili more than 30 years of program management experience in the drug development industry, with extensive clinical and regulatory expertise that includes direct involvement with 20 programs that became commercialized products, including Lipitor™ and Difcid™. His career includes positions in program management, drug product team leadership, clinical pharmacology, clinical development, and administration in large pharmaceutical, biotechnology, and generic drug companies. He has worked across a broad range of development positions in companies including Shire Pharmaceuticals (Takeda), MedImmune (AstraZeneca), and Otsuka America Pharmaceuticals. He also has held multiple consulting roles, outsourcing his drug development expertise to help build and lead teams for companies in need of functional area expertise. Dr. Cilla earned his Doctor of Pharmacy from the University of Michigan and an MBA from the University of Phoenix.
Myriam Triest, PhD
Senior Director, Product Development
Myriam Triest brings over 15 years of experience as a drug development professional and chemist to her role as Director of Manufacturing and Pharmaceutical Development. She manages the chemical, regulatory, and quality aspects of Appili’s drug development pipeline. In her previous role as Director of Product Development at Locemia Solutions (Montreal), Dr. Triest supported the development of a combination drug candidate from discovery through a successful phase 3 clinical program that was ultimately licensed to Eli Lilly for $150M USD upfront plus milestones. In addition, she brings to Appili experience as a vice president of a clinical research organization with a wide range of drug development programs, including small molecules, peptides, and medical devices. She earned her PhD from Katholieke Universiteit Leuven, Belgium and completed her post-doctorate fellowship at Université de Montréal.
Stéphane Paquette, PhD
Senior Director, Corporate Development
As Senior Director, Corporate Development, Stéphane Paquette directs evaluation and licensing activities for Appili, as well as key stakeholder and partner management. Dr. Paquette brings extensive infectious disease and R&D experience to his role at Appili, with over 10 years in industry and leading academic institutions. Prior to joining Appili, Dr. Paquette was a researcher at the University Health Network / University of Toronto studying emerging viral pathogens, immune responses to infection and vaccination, and novel antiviral compounds. Previously, Dr. Paquette was Associate Scientist at Abbott Point of Care where he conducted exploratory R&D on novel diagnostic assays. He is author on 14 peer-reviewed publications in the fields of infectious disease and biochemistry, and holds a PhD from the University of Toronto with a BSc in Microbiology & Immunology from McGill University.
Director, Regulatory Affairs
Jason McEwan has over 15 years of regulatory experience, including both as a regulator for Health Canada (HC) and as a consultant to the regulated pharmaceutical industry in the US and Canada, with a focus on specialty products. Jason has advised sponsors on regulatory development requirements, including Investigational New Drug filings (INDs) and Clinical Trial Applications (CTAs), led HC/FDA meetings, and supported flagship product marketing application and approvals for innovative products. Jason was recognized as part of a team with the Deputy Minister’s Award, the highest in the civil service, for the highest contribution to the healthcare of Canadians; he was heavily involved in the Chalk River shutdown and Isotope Crisis of 2008 and Swine Flu vaccine inoculation campaign of 2009. Jason holds a BSc (Hon) in Biochemistry from Carleton University in Ottawa, Canada.